Navigation Links
Accera, Inc. to Present at Upcoming Investor Conferences
Date:3/25/2009

BROOMFIELD, Colo., March 25 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) disorders, today announced that the company will be participating at two upcoming healthcare investor conferences.

Dr. Steve Orndorff, Founder, President and CEO, will speak at the 2nd Annual BIO Venture Conference on April 1 at 10:15 a.m. EDT at the Sheraton Boston Hotel in Boston, MA. On April 9 at 11:30 a.m. PDT, he will present at the C21 BioVentures Conference at the Meritage Resort in Napa Valley, CA.

In early March, the company launched Axona(TM), a medical food available only by prescription for mild-to-moderate Alzheimer's disease. Dr. Orndorff will provide an overview of Accera and its technology pipeline and also provide an update on the successful nationwide launch of Axona.

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops product breakthroughs in treating central nervous system disorders. Accera's novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments. Through its proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies by providing an alternative energy source to the brain.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.

    Contacts:
    Media:                                  Investors:
    Gregory Tiberend                        Cecelia Heer
    Richard Lewis Communications, Inc.      Richard Lewis Communications, Inc.
    Ph: (212) 827-0020                      Ph: (212) 827-0020
    gtiberend@rlcinc.com                    cheer@rlcinc.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
2. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
3. Accera, Inc. Completes $35 Million Series C Financing
4. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
5. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
6. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
7. Avicena Group to Present at Noble Financial Conference
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
Breaking Biology Technology:
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
Breaking Biology News(10 mins):